Atossa Therapeutics opened at $2.03, in line with its previous close of $2.03. In the last trading session, the stock traded between $1.81 and $2.06. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Atossa Therapeutics is now worth
$ 5.05
Resulting in a loss of
$ 94.95 (94.95%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.08 (-4.14%)
Day High
$2.06
Day Low
$1.81
Day Open
$2.03
Prev Close
$2.03
Volume
91,159
1W Return
-7.99%
1M Return
-18.41%
3M Return
-16.66%
6M Return
-64.62%
1Y Return
-84.33%
Fundamentals
Market Cap ($ Mn)
19
PE Ratio
-
PB Ratio
0.96
PEG Ratio
-
ROE
-61.29%
ROCE
-65.48%
EPS (TTM)
$-0.56
Investment Returns
1 Week
-7.99%
1 Month
-18.41%
3 Months
-16.66%
6 Months
-64.62%
9 Months
-51.95%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
19Oct
Atossa Therapeutics shares to trade with one stapled CVR from Oct 19
Each Atossa Therapeutics share will have one contingent value right (CVR) attached starting October 19, 2026. CVRs remain stapled to shares and cannot trade separately until the Board elects to detach them. Transfers of shares automatically include the attached CVR; no separate CUSIP exists while stapled. Shares issued after the record date but before detachment also carry one attached CVR.
24 days ago
1Oct
Ascendiant Capital raises Atossa Therapeutics price target to $25
Ascendiant Capital maintains Buy rating on Atossa Therapeutics. Price target raised from $24 to $25. Analyst Edward Woo issued the rating update.
1mo ago
7Aug
Atossa Therapeutics Q2 Results: EPS beats estimates despite loss
Atossa Therapeutics delivered Q2 EPS of $(0.95), beating the $(1.02) estimate by 6.86%. However, losses widened 171.43% YoY from $(0.35), signaling ongoing operational pressures despite the quarterly surprise.
3mo ago
28Jul
Atossa Therapeutics publishes study on novel endoxifen compounds for breast cancer
Atossa Therapeutics published a preclinical study in npj Breast Cancer detailing five novel (Z)-endoxifen-related compounds. These entities showed anti-cancer activity in ERα+ breast cancer models, including those with ESR1 mutations, suggesting potential for combination with abemaciclib.
3mo ago
21Jul
Atossa Therapeutics presents (Z)-Endoxifen data at AACR conference
Atossa Therapeutics presented preclinical data on (Z)-Endoxifen at the 2026 AACR Special Conference, highlighting its dual estrogen receptor and PKC-β/AKT pathway modulation as a potential therapy for McCune-Albright Syndrome. The conference was held in Vancouver, BC, Canada, from July 18-20, 2026.
3mo ago
11Jun
Atossa Therapeutics raises $4.5m in registered direct offering
Atossa Therapeutics entered a securities purchase agreement for 1,363,638 shares and warrants, expecting $4.5 million in gross proceeds. Potential additional proceeds of $12 million are possible if warrants are fully exercised. The closing is anticipated on June 12, 2026.
